Dasatinib Use and Risk of Cytomegalovirus Reactivation After Allogeneic Hematopoietic-Cell Transplantation

Clin Infect Dis. 2017 Aug 1;65(3):510-513. doi: 10.1093/cid/cix325.

Abstract

Viral infections have been reported with dasatinib use, but its cytomegalovirus risk after hematopoietic-cell transplantation (HCT) is not known. We found that post-HCT dasatinib use increased the risk of cytomegalovirus reactivation (adjusted hazard ratio, 7.65; 95% confidence interval, 1.84-31.7), controlling for acute graft-versus-host disease, in 109 patients with Philadelphia-chromosome-positive malignancies.

Keywords: acute lymphoblastic leukemia; chronic myelogenous leukemia; cytomegalovirus; dasatinib; hematopoietic cell transplantation.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Cohort Studies
  • Cytomegalovirus Infections / chemically induced
  • Cytomegalovirus Infections / epidemiology*
  • Cytomegalovirus*
  • Dasatinib / adverse effects*
  • Dasatinib / therapeutic use
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / epidemiology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy
  • Middle Aged
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • Young Adult

Substances

  • Antineoplastic Agents
  • Dasatinib